Ottawa, June 29, 2021 – Innovative Medicines Canada views Health Canada’s decision to delay implementation of the Patented Medicine Prices Review Board (PMPRB) regulatory reforms to January 1, 2022, as a renewed opportunity to examine the potential impact of these reforms, as well as affording time to generate more effective alternative solutions.
The federal government is urged to meaningfully consult with industry, patient groups and other stakeholders to support sustainable access to lifesaving drugs and a thriving life sciences sector that will be an integral part of Canada’s economic recovery. This additional time should be used to work together to modernize PMPRB’s regulations in a way that ensures access to innovative medicines and vaccines, clinical trials, R&D, and investment.
IMC and its member companies maintain that proceeding with the PMPRB current reforms will have significant negative impact, and call on the federal government to join us and health sector stakeholders in a whole-of-government approach that will work for Canada and all Canadians.
About Innovative Medicines Canada
Innovative Medicines Canada is the national association representing the voice of Canada’s innovative pharmaceutical industry. The association advocates for policies that enable the discovery, development, and delivery of innovative medicines and vaccines to improve the lives of all Canadians and supports the members’ commitment to being a valued partner in the Canadian healthcare system. The association represents 47 companies who invest nearly $1.2 billion in R&D annually, fueling Canada’s knowledge-based economy, while contributing $8 billion to Canada’s economy. Guided by the Code of Ethical Practices, all members work with governments, private payers, healthcare professionals, and stakeholders in a highly ethical manner.
– 30 –
For further information:
Corinne Crichlow
Director, Media and Public Relations
Telephone: 613.236.0455, ext. 245
E-mail: ccrichlow@imc-mnc.ca
